Related Experiment Video

Updated: Mar 18, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

Larysa Sanchez1, Yucai Wang1, David S Siegel2

  • 1Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.

Journal of Hematology & Oncology
|July 2, 2016
PubMed

Insights

Daratumumab, a CD38-targeting monoclonal antibody, effectively treats multiple myeloma (MM) by inducing cancer cell death. Its FDA approval marks a significant advancement in MM therapy.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Multiple myeloma (MM) is a cancer of plasma cells.
  • CD38 is a protein highly expressed on MM cells.

Purpose of the Study:

  • To evaluate daratumumab as a novel treatment for multiple myeloma.
  • To highlight the mechanisms of action and clinical efficacy of daratumumab.

Main Methods:

  • Daratumumab, a human monoclonal antibody, targets CD38.
  • Preclinical studies investigated mechanisms like complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis.

Main Results:

  • Daratumumab demonstrated efficacy in clinical trials for multiple myeloma.
  • The antibody induces MM cell death via multiple immune-mediated and direct cytotoxic pathways.

Conclusions:

  • Daratumumab is an effective and safe treatment option for multiple myeloma.
  • Daratumumab is the first monoclonal antibody approved by the FDA for MM treatment.

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K